Foot Anstey supports Prescient’s continued growth with Dolon acquisition

National law firm Foot Anstey has advised Prescient, a strategic partner to the biopharmaceutical industry backed by Bridgepoint, on its acquisition of London‑based pricing and market access consultancy Dolon Ltd, expanding Prescient’s specialist capabilities across the drug lifecycle.

Dolon operates internationally and provides advisory expertise on market access, pricing and reimbursement strategies for rare diseases and oncology. The combination broadens Prescient’s ability to support pharmaceutical and biotechnology clients across complex global commercial and regulatory landscapes.

This transaction follows Prescient’s acquisition of Uptake Strategies Ltd, a global healthcare consultancy, which Foot Anstey also advised on in January 2026. Both transactions were delivered to tight and evolving timetables, with exchange occurring within three weeks of instruction on each deal.

Dominic Cromwell, Principal Director at Foot Anstey, said: “This acquisition is another important milestone for Prescient as it continues to execute an ambitious growth strategy in a highly competitive and fast-moving sector. Being trusted on multiple transactions within compressed timeframes reflects the strength of our relationship and our ability to collaborate seamlessly across teams to deliver when stakes are high.”

The Foot Anstey team was led by Principal Director Dominic Cromwell, supported by Senior Associate Bethany Donnelly and Associates Megan Berry and Colin Shear, alongside colleagues from across the firm’s corporate, banking, commercial, real estate, employment, pensions, data protection, intellectual property, IT and regulatory practices.